Correlation Between Aclarion and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both Aclarion and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aclarion and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aclarion and Dermata Therapeutics Warrant, you can compare the effects of market volatilities on Aclarion and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aclarion with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aclarion and Dermata Therapeutics.

Diversification Opportunities for Aclarion and Dermata Therapeutics

0.16

Correlation Coefficient

Aclarion  Dermata Therapeutics

Average diversification

The 3 months correlation between Aclarion and Dermata is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Aclarion and Dermata Therapeutics Warrant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Aclarion is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aclarion are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Aclarion i.e., Aclarion and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Aclarion and Dermata Therapeutics

Given the investment horizon of 90 days Aclarion is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Aclarion is 45.74 times less risky than Dermata Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Dermata Therapeutics Warrant is currently generating about 0.27 of returns per unit of risk over similar time horizon. If you would invest  1.40  in Dermata Therapeutics Warrant on September 15, 2024 and sell it today you would lose (0.30) from holding Dermata Therapeutics Warrant or give up 21.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	45.24%
Values	Daily Returns

Aclarion  vs.  Dermata Therapeutics Warrant

Aclarion

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aclarion has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Dermata Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Aclarion and Dermata Therapeutics

The main advantage of trading using opposite Aclarion and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aclarion position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind Aclarion and Dermata Therapeutics Warrant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.